GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00102128 | Oral cavity | OSCC | response to ionizing radiation | 99/7305 | 148/18723 | 5.49e-12 | 2.08e-10 | 99 |
GO:00094114 | Oral cavity | OSCC | response to UV | 99/7305 | 149/18723 | 1.01e-11 | 3.70e-10 | 99 |
GO:004232619 | Oral cavity | OSCC | negative regulation of phosphorylation | 214/7305 | 385/18723 | 2.30e-11 | 7.74e-10 | 214 |
GO:007190010 | Oral cavity | OSCC | regulation of protein serine/threonine kinase activity | 201/7305 | 359/18723 | 3.90e-11 | 1.27e-09 | 201 |
GO:004339318 | Oral cavity | OSCC | regulation of protein binding | 121/7305 | 196/18723 | 8.92e-11 | 2.73e-09 | 121 |
GO:000193319 | Oral cavity | OSCC | negative regulation of protein phosphorylation | 191/7305 | 342/18723 | 1.58e-10 | 4.62e-09 | 191 |
GO:003367317 | Oral cavity | OSCC | negative regulation of kinase activity | 140/7305 | 237/18723 | 2.74e-10 | 7.57e-09 | 140 |
GO:000646918 | Oral cavity | OSCC | negative regulation of protein kinase activity | 127/7305 | 212/18723 | 5.21e-10 | 1.37e-08 | 127 |
GO:000931416 | Oral cavity | OSCC | response to radiation | 241/7305 | 456/18723 | 9.76e-10 | 2.40e-08 | 241 |
GO:19019875 | Oral cavity | OSCC | regulation of cell cycle phase transition | 209/7305 | 390/18723 | 2.79e-09 | 6.42e-08 | 209 |
GO:00457864 | Oral cavity | OSCC | negative regulation of cell cycle | 206/7305 | 385/18723 | 4.28e-09 | 9.55e-08 | 206 |
GO:190165316 | Oral cavity | OSCC | cellular response to peptide | 194/7305 | 359/18723 | 4.31e-09 | 9.57e-08 | 194 |
GO:003109816 | Oral cavity | OSCC | stress-activated protein kinase signaling cascade | 141/7305 | 247/18723 | 5.74e-09 | 1.25e-07 | 141 |
GO:005109920 | Oral cavity | OSCC | positive regulation of binding | 105/7305 | 173/18723 | 5.88e-09 | 1.26e-07 | 105 |
GO:003158917 | Oral cavity | OSCC | cell-substrate adhesion | 193/7305 | 363/18723 | 2.48e-08 | 4.82e-07 | 193 |
GO:001081019 | Oral cavity | OSCC | regulation of cell-substrate adhesion | 126/7305 | 221/18723 | 4.02e-08 | 7.55e-07 | 126 |
GO:00718979 | Oral cavity | OSCC | DNA biosynthetic process | 106/7305 | 180/18723 | 4.86e-08 | 8.95e-07 | 106 |
GO:005140316 | Oral cavity | OSCC | stress-activated MAPK cascade | 134/7305 | 239/18723 | 6.02e-08 | 1.09e-06 | 134 |
GO:00310999 | Oral cavity | OSCC | regeneration | 114/7305 | 198/18723 | 8.54e-08 | 1.50e-06 | 114 |
GO:004340917 | Oral cavity | OSCC | negative regulation of MAPK cascade | 105/7305 | 180/18723 | 1.10e-07 | 1.87e-06 | 105 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MEN1 | SNV | Missense_Mutation | novel | c.676N>A | p.Leu226Met | p.L226M | O00255 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A04N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
MEN1 | SNV | Missense_Mutation | | c.1817C>G | p.Ser606Cys | p.S606C | O00255 | protein_coding | deleterious(0.01) | possibly_damaging(0.82) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MEN1 | SNV | Missense_Mutation | | c.323G>C | p.Arg108Pro | p.R108P | O00255 | protein_coding | tolerated(0.07) | possibly_damaging(0.7) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MEN1 | SNV | Missense_Mutation | | c.1084G>C | p.Asp362His | p.D362H | O00255 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A6IX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MEN1 | SNV | Missense_Mutation | rs377715802 | c.1040N>T | p.Ala347Val | p.A347V | O00255 | protein_coding | deleterious(0) | possibly_damaging(0.726) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MEN1 | SNV | Missense_Mutation | | c.479N>T | p.Ser160Phe | p.S160F | O00255 | protein_coding | tolerated(1) | benign(0.009) | TCGA-BH-A0DK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
MEN1 | SNV | Missense_Mutation | | c.550G>A | p.Glu184Lys | p.E184K | O00255 | protein_coding | deleterious(0) | probably_damaging(0.934) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MEN1 | deletion | Frame_Shift_Del | | c.1700_1706delNNNNNNN | p.Lys567SerfsTer24 | p.K567Sfs*24 | O00255 | protein_coding | | | TCGA-BH-A18R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MEN1 | deletion | Frame_Shift_Del | | c.225_229delNNNNN | p.Thr76LeufsTer39 | p.T76Lfs*39 | O00255 | protein_coding | | | TCGA-E9-A1N5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MEN1 | insertion | Frame_Shift_Ins | rs767319284 | c.1561_1562insC | p.Arg521ProfsTer15 | p.R521Pfs*15 | O00255 | protein_coding | | | TCGA-E9-A228-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | CHLORHEXIDINE HYDROCHLORIDE | CHLORHEXIDINE HYDROCHLORIDE | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | FURAFYLLINE | FURAFYLLINE | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | TCMDC-123591 | CHEMBL588234 | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | CYCLIRAMINE MALEATE | CYCLIRAMINE MALEATE | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | METHYLENE BLUE | METHYLENE BLUE | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | TANNIC ACID | TANNIC ACID | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | SJ000029700 | CHEMBL591864 | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | TRIMETREXATE | TRIMETREXATE | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | TCMDC-124518 | CHEMBL527584 | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | TRACAZOLATE | TRACAZOLATE | |